Professional
Added to YB: 2024-08-05
Pitch date: 2024-06-30
INSM [bullish]
Insmed Incorporated
+196.48%
current return
Author Info
No bio for this author
Company Info
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Market Cap
$42.0B
Pitch Price
$66.45
Price Target
N/A
Dividend
N/A
EV/EBITDA
-43.68
P/E
-31.68
EV/Sales
91.89
Sector
Biotechnology
Category
growth
Artisan Mid Cap Fund New Position: Insmed Incorporated
INSM: Biotech w/ FDA-approved Arikayce for resistant lung disease. Late-stage Brensocatib for bronchiectasis (1M+ patients US/EU/JP) has multi-billion $ potential. Positive Ph3 results. Pipeline may treat other respiratory diseases. Huge unmet need in respiratory market. Initiated position post-trial success.
Read full article (1 min)